Company profile · Biotech & medical
Polaris Group
北極星藥業集團股份有限公司 · 6550
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Polaris Group focuses on the research, development, and manufacturing of new drugs as a biotechnical company specializing in novel cancer treatments.[1]
Its primary research drug, ADI-PEG 20 (pegargiminase), is a biologic agent currently in clinical development and late-stage clinical trials for a wide range of cancer indications, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, and acute myeloid leukemia.[2]
The company holds various patents involving pegargiminase, encompassing formulations and uses.[3]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$2m | +894.8% | -69.9% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$8m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Polaris Group |
|---|---|
| Chinese name | 北極星藥業集團股份有限公司 |
| Stock code | 6550 (TWSE) |
| Industry | Biotech & medical |
| Founded | 09 Feb 2006 |
| Listed | 06 Jun 2022 |
| Paid-in capital | NT$4.6bn |
| Chairman | 陳賢哲 |
| President | 陳賢哲(暫代) |
| Headquarters | 7F, NO.298, Ruiguang Rd., Neihu Dist Taipei, Taiwan |
| Website | https://www.polarispharma.com |
| Official business description | 新藥研發製造 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 北極星藥業集團股份有限公司 · mops · retrieved 04 Nov 2026
- 首頁 - Polaris Group · website · retrieved 04 Nov 2026
- 管理團隊 - Polaris Group · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list